A Multicenter, Open-label, Randomized Controlled Trial Evaluating the Efficacy and Safety of Romiplostim N01 in the Treatment of Thrombocytopenia Associated With Concurrent/Sequential Chemoradiotherapy and Chemotherapy Combined With/Without Immu

• Status: NOT_YET_RECRUITING
• Trial end date: 2028-12-31

Summary

The purpose of this clinical trial is to evaluate the safety and efficacy of Romiplostim N01 in patients with solid tumors who are undergoing concurrent/sequential radiotherapy and chemotherapycombined with/without immunotherapy-related thrombocytopenia.

All eligible patients will be stratified and randomly assigned based on baseline platelet countStratification factors: whether the baseline platelet count of the patients is greater than 5010\^9/L. . All patients will be randomly assigned in a 1:1 ratio to experimental group or control group:

Experimental group: Romiplostim N01 (N=53) Control groupHuman Interleukin-11(rhlL-11) (N=53) The main questions this trial aims to answer are: 1. The proportion of patients who received platelet transfusion due to thrombocytopenia during the treatment process, as well as the adjustment, delay and discontinuation of radiotherapy and chemotherapy doses 2. Can patients treated with Romiplostim N01 restore their platelet count to 10010\^9/L and what is the response rate of patients during the treatment (response criteria: no need for platelet transfusion and PLT increase 5010\^9/L or at least twice the baseline or PLT increase to 10010\^9/L)3. The safety and tolerance of Romiplostim N01 in treating CTIT.

• Phase: NA

Details

• Lead Sponsor: Jun wang